SHANGHAI – Uni-Bio Science Group Ltd. has submitted a new drug application (NDA) to the CFDA for Uni-PTH, a biosimilar of Forteo (teriparatide, Eli Lilly and Co.). The Hong Kong-listed firm is planning for Uni-PTH – a parathyroid hormone 1-34 analogue to treat postmenopausal women with osteoporosis – to be on the market in Mainland China by 2017 at the earliest.